The Biosimilar Patent Dance, Exclusivity, And Unintended Innovation
This article was originally published in PharmAsia News
Executive Summary
As brand firms are learning with biosimilars, laws can turn out in unexpected ways – but there may well be some pleasant surprises in the U.S. 21st Century Cures legislation.